Consensus Mesoblast Limited

Equities

MSB

AU000000MSB8

Market Closed - Australian S.E. Other stock markets 02:10:45 2024-04-26 am EDT			5-day change	1st Jan Change
0.93 ^AUD	+1.64%		+21.57%	+200.00%

Apr. 01	ADRs End Higher; Connect Biopharma Climbs 26%	DJ
Mar. 28	ADRs End Lower; NuCana Slides 15%	DJ

Evolution of the average Target Price on Mesoblast Limited

Price target over the last 5 years

History of analyst recommendation changes

afd.wpqPj_oHJ-AFY6UMhpIpLvACyg8DPf4XGD58-cQK-xk.r9vn3JBEd6RaL81fzdYRdJxvqz9oWItZfH8OioVduDTx0u64sH1VonUbnQ~13cab77dcd9e538f76de8591f7b40beb

Analyst Recommendations on Mesoblast Limited

Fed Rate Outlook Weakens Exchange-Traded Funds, Equity Futures Premarket Thursday	23-09-21	MT
Cantor Fitzgerald Adjusts Price Target on Mesoblast to $17 From $23, Maintains Overweight Rating	23-08-31	MT
Maxim Downgrades Mesoblast to Hold From Buy	23-08-07	MT
Piper Sandler Downgrades Mesoblast to Neutral From Overweight, Adjusts Price Target to $2 From $7	23-08-04	MT
William Blair Downgrades Mesoblast to Market Perform From Outperform	23-08-04	MT
Chardan Trims Price Target on Mesoblast to $1.50 From $2, Maintains Sell Rating	23-08-04	MT
Chardan Cuts Price Target on Mesoblast to $2 From $2.50 Reflecting Increased Share Count Dilution, Reiterates Sell Rating	23-05-30	MT
Cantor Fitzgerald Reiterates Mesoblast at Overweight With $23 Price Target	23-02-01	MT
Jefferies Downgrades Mesoblast to Hold From Buy	22-12-06	MT
Piper Sandler Starts Mesoblast at Overweight With $7 Price Target	22-09-06	MT
Chardan Lowers Mesoblast's Price Target to $2.50 From $6.50, Maintains Sell Rating	22-06-03	MT
MESOBLAST : Jefferies Downgrades Mesoblast to Hold From Buy	21-08-31	MT
MESOBLAST : Chardan Adjusts Mesoblast's Price Target to $6.50 From $7.50, Maintains Sell Rating	21-08-31	MT
Mesoblast : COVID-19 Drug Remestemcel-L's ARDS Trial Enhances Survival Rate in Patients	21-07-19	MT
MESOBLAST : Maxim Group Upgrades Mesoblast to Buy From Hold, Sets $18 Price Target	21-04-07	MT
MESOBLAST : Jefferies & Co Downgrades Mesoblast to Hold From Buy	21-01-19	MT
MESOBLAST : Maxim Downgrades Mesoblast to Hold From Buy	20-12-22	MT
MESOBLAST : RBC Capital Adjusts Mesoblast's Price Target to $11 From $12, Maintains Sector Perform-Speculative Risk Rating	20-12-15	MT
MESOBLAST : Chardan Downgrades Mesoblast to Sell From Neutral, Adjusts Price Target to $7.50 From $5.50	20-12-04	MT
MESOBLAST : HC Wainwright Adjusts Mesoblast's Price Target to $20 from $19, Keeps Buy Rating	20-11-20	MT